Comparing the current results to its competitors, Soleno Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 0 % year on year. The revenue growth was below Soleno Therapeutics Inc's competitors' average revenue growth of 257.84 %, achieved in the same quarter.
Soleno Therapeutics Inc's Comment on Competition and Industry Peers
The competitive landscape involves challenges such as attracting and retaining key management and personnel, protecting intellectual property rights, and addressing potential advantages held by competitors in securing funding or developing products. Additional risks include business interruptions caused by natural disasters, compliance with applicable laws and regulations, product liability claims, and the utilization of net operating loss carryforwards to offset future taxable income.
November 6, 2025
In a dramatic turn of events for Soleno Therapeutics, Inc. (NASDAQ: SLNO), investors watched their holdings plummet by nearly 28% as the company disclosed underwhelming results regarding its oral treatment for hyperphagia, VYKAT XR. On November 5, 2025, the San Francisco-based biopharmaceutical company reported that the expectations for VYKAT XR had not been met, sending shockwaves through the investment community and prompting intense scrutiny.VYKAT XR, developed as a once-daily oral tablet, was touted as a potential breakthrough in treating hyperphagia, a severe and challenging symptom associated with Prader-Willi syndrome (PWS). This rare genetic disorder affects individuals in profound ways, manifesting ...
Amicus Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare and orphan diseases.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Sources:
Soleno Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Soleno Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
